Biocon Biologics and its partner Viatris get EC nod for biosimilar Bevacizumab
Biocon Limited’s subsidiary Biocon Biologics Ltd has informed the bourses that Abevmy 100 & 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. has received marketing authorisation approval from European Commission (EC), following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
Abevmy 100 & 400 mg, a biosimilar of Bevacizumab, is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as a part of a specific regimen.
The centralised marketing authorisation granted by the EC is valid in all EU member states as well as in the European Economic Area (EEA) countries such as Iceland, Liechtenstein, and Norway.
As per the company’s management, the European Commission’s approval of biosimilar Bevacizumab will enable the company to offer this biologic therapy to cancer patients in the EU along with its partner Viatris. The addition of biosimilar Bevacizumab will strengthen its portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim.
On Monday, the stock of Biocon opened 1.1 per cent higher at Rs 401.95 from its previous close of Rs 397.40 on BSE.